People who travel to areas where meningococcal disease is more common, or who travel to mass gatherings such as the Hajj, are strongly recommended to receive MenACWY vaccines
MenACWY vaccines are strongly recommended for people who are planning travel that may involve a greater risk of exposure to meningococcal serogroups A, C, W-135 and Y.
These people include:
- people travelling to, or living in, parts of the world where epidemics of serogroups A, C, W-135 or Y meningococcal disease occur, particularly the ‘meningitis belt’ of sub-Saharan Africa (see Accessing up-to-date travel information in Vaccination for international travellers)
- people travelling to mass gatherings, such as pilgrims travelling to the Hajj
The Saudi Arabian authorities require documentation of vaccination for country entry visas. See Vaccination for international travellers.
The vaccine brand and doses needed for primary vaccination depend on the person’s age when they start the vaccine course, and are the same as for healthy people. Details on the number of doses and dose intervals are in:
- Table. Recommendations for meningococcal vaccines for healthy people aged ≥2 years, by age and vaccine brand
- Table. Recommendations for immunisation of infants and children aged <2 years using meningococcal ACWY vaccines, by age and vaccine brand
People who have received a full primary course of MenACWY vaccine and have an ongoing increased risk of meningococcal disease due to travel are recommended to receive a single booster dose of MenACWY vaccine. The timing of booster doses depends on the person’s age when they finished the primary vaccination course:
- People who were ≤6 years of age when they finished the primary course should receive a booster dose 3 years after the last dose of the primary course, then every 5 years after that while the risk is ongoing.
- People who were ≥7 years of age when they finished the primary course should receive a booster dose every 5 years while the risk is ongoing.
People who have previously received a meningococcal polysaccharide vaccine
People with ongoing increased risk of meningococcal disease due to travel who have previously received a quadrivalent meningococcal polysaccharide vaccine (4vMenPV) are recommended to receive 1 dose of MenACWY conjugate vaccine. They should receive this dose about 2 years after the most recent dose of 4vMenPV, with a recommended minimum interval of 6 months. They are also recommended to receive booster doses of MenACWY vaccine (see Booster doses).
- quadrivalent meningococcal polysaccharide vaccine
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/recommendations/people-who-travel-to-areas-where-meningococcal-disease-is-more-common-or-who-travel.